{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:10:31Z","timestamp":1781629831675,"version":"3.54.5"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Peripheral T-cell lymphomas (PTCLs) are a heterogenous yet aggressive group of lymphomas that arise from mature T- or NK-cell precursors. Nodal PTCLs include anaplastic large-cell lymphoma, PTCL not otherwise specified, and follicular helper T-cell lymphomas. Recent advances in understanding these heterogenous diseases have prompted investigation of novel agents to improve on treatment. Brentuximab vedotin, a CD30 antibody-drug conjugate, has been incorporated into frontline treatment regimens of CD30-expressing PTCLs based on the ECHELON-2 trial. Multiple ongoing trials are evaluating the addition of other targeted agents in the frontline and relapsed\/refractory setting. These include single-agent brentuximab vedotin, histone deacetylase inhibitors, duvelisib, ruxolitinib, EZH2 inhibitors, and azacitidine, among others. Follicular helper T-cell lymphomas, given frequent mutations in epigenetic regulator genes, may preferentially respond to agents such as histone deacetylase inhibitors, EZH2 inhibitors, and hypomethylating agents. As these therapies evolve in their use for both relapsed\/refractory disease and then into frontline treatment, subtype-specific therapy will likely help personalize care for patients with PTCL.<\/jats:p>","DOI":"10.1182\/hematology.2024000530","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:05:17Z","timestamp":1733497517000},"page":"54-61","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["BV and beyond: how to incorporate novel agents into PTCL management"],"prefix":"10.1182","volume":"2024","author":[{"given":"Imran A.","family":"Nizamuddin","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"25","key":"2024121115464881000_hem2024000530C1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024121115464881000_hem2024000530C2","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"2024121115464881000_hem2024000530C3","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121115464881000_hem2024000530C4","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2018-99-112076","article-title":"Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the international ACT-1\/2 phase III trials","volume":"132","author":"Altmann","year":"2018","journal-title":"Blood"},{"issue":"14","key":"2024121115464881000_hem2024000530C5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024121115464881000_hem2024000530C6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/bloodadvances.2023011095","article-title":"Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial","volume":"8","author":"Iyer","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2024121115464881000_hem2024000530C7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2024121115464881000_hem2024000530C8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2021-151105","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-expressing peripheral T-cell lymphomas","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood"},{"issue":"18","key":"2024121115464881000_hem2024000530C9","first-page":"2194","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"issue":"25","key":"2024121115464881000_hem2024000530C10","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024121115464881000_hem2024000530C11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am J Hematol"},{"issue":"9","key":"2024121115464881000_hem2024000530C12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18","key":"2024121115464881000_hem2024000530C13","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well- tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2024121115464881000_hem2024000530C14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00277-015-2309-z","article-title":"Modified ESHAP regimen for relapsed\/refractory T cell lymphoma: a retrospective analysis","volume":"94","author":"Kogure","year":"2015","journal-title":"Ann Hematol"},{"issue":"11","key":"2024121115464881000_hem2024000530C15","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","article-title":"Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial","volume":"94","author":"Park","year":"2015","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"2024121115464881000_hem2024000530C16","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","article-title":"Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma","volume":"14","author":"Zelenetz","year":"2003","journal-title":"Ann Oncol"},{"issue":"20","key":"2024121115464881000_hem2024000530C17","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"28","key":"2024121115464881000_hem2024000530C18","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children's Oncology Group Study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024121115464881000_hem2024000530C19","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"2024121115464881000_hem2024000530C20","first-page":"7","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume-title":"J Hematol Oncol","author":"Coiffier","year":"2014"},{"issue":"4","key":"2024121115464881000_hem2024000530C21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hon.2320","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"35","author":"Pro","year":"2017","journal-title":"Hematol Oncol"},{"issue":"19","key":"2024121115464881000_hem2024000530C22","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"2024121115464881000_hem2024000530C23","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024121115464881000_hem2024000530C24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2024121115464881000_hem2024000530C25","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2022-156789","article-title":"Oral azacytidine in patients with relapsed\/refractory angioimmunoblastic T-cell lymphoma: final analysis of the Oracle phase III study","volume":"140","author":"Dupuis","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"2024121115464881000_hem2024000530C26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/hon.3164_367","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial expansion phase: outcomes by baseline histology","volume":"41","author":"Mehta-Shah","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2024121115464881000_hem2024000530C27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2023-180137","article-title":"A multicenter phase2 trial of linperlisib in relapsed or refractory peripheral T\/NK cell lymphomas","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"issue":"26","key":"2024121115464881000_hem2024000530C28","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121115464881000_hem2024000530C29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2023-172962","article-title":"Golidocitinib in treating refractory or relapsed peripheral T- cell lymphoma: full analysis of the multinational pivotal study results (JACKPOT8)","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121115464881000_hem2024000530C30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2023-179304","article-title":"Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121115464881000_hem2024000530C31","doi-asserted-by":"crossref","first-page":"8857","DOI":"10.1182\/blood-2022-159177","article-title":"ITK inhibitor induces dose-dependent Th1 skewing in normal T cells and is active in refractory T cell lymphomas","volume":"140","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024121115464881000_hem2024000530C32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024121115464881000_hem2024000530C33","doi-asserted-by":"crossref","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2024121115464881000_hem2024000530C34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- Cell Consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2024121115464881000_hem2024000530C35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.18885","article-title":"Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma","volume":"202","author":"Stuver","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"2024121115464881000_hem2024000530C36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bjh.12326","article-title":"Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma","volume":"162","author":"Oki","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"2024121115464881000_hem2024000530C37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"2024121115464881000_hem2024000530C38","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial [published online 17 Jun 2024]","author":"Horwitz","journal-title":"Nat Med"},{"issue":"5","key":"2024121115464881000_hem2024000530C39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024121115464881000_hem2024000530C40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ajh.26288","article-title":"Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts","volume":"96","author":"Mehta-Shah","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/54\/2346636\/54nizamuddin.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/54\/2346636\/54nizamuddin.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:14:14Z","timestamp":1733948054000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/54\/526172\/BV-and-beyond-how-to-incorporate-novel-agents-into"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000530","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}